KEYNOTE-062 study: Pembrolizumab as treatment for advanced gastroesophageal junction and gastric...
Dr Josep Tabernero talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the use of immunotherapy agent pembrolizumab as treatment for advanced gastroesophageal junction and gastric cancers. He explains that this study had three arms: single agent pembrolizumab, pembrolizumab and chemotherapy, or chemotherapy plus placebo. Dr Tabernero reports that the comparison of pembrolizumab and chemotherapy met the primary endpoint of non-inferiority for overall survival favouring pembrolizumab. Sign up to ecancer for free to receive tailored email alerts for more videos like this. ecancer.org/account/register.php
